期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 54, 期 6, 页码 2732-2734出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01768-09
关键词
-
资金
- Johnson & Johnson Pharmaceutical Research and Development
- BMA Medical Foundation, Inc
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin were assessed against 20 carbapenem-resistant clinical isolates with different mechanisms of carbapenem resistance. Bactericidal activity was achieved in 90% of all bacteria assayed using combinations of polymyxin B, doripenem, and rifampin against five each of the carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli isolates studied. Combinations with these antibacterials may provide a strategy for treatment of patients infected with such organisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据